Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

L. Doherty; D. C. Gigas; S. Kesari; J. Drappatz; R. Kim; J. Zimmerman; L. Ostrowsky; P. Y. Wen

doi:10.1212/01.wnl.0000223844.77636.29

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

L. Doherty, D. C. Gigas, S. Kesari, J. Drappatz, R. Kim, J. Zimmerman, L. Ostrowsky, P. Y. Wen

Research output: Contribution to journal › Article › peer-review

155 Scopus citations

Abstract

Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.

Original language	English (US)
Pages (from-to)	156-158
Number of pages	3
Journal	Neurology
Volume	67
Issue number	1
DOIs	https://doi.org/10.1212/01.wnl.0000223844.77636.29
State	Published - Jul 2006
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/01.wnl.0000223844.77636.29

Cite this

@article{aa45b9f19e7943eeb55dec5cbd23b7c3,

title = "Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas",

abstract = "Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.",

author = "L. Doherty and Gigas, {D. C.} and S. Kesari and J. Drappatz and R. Kim and J. Zimmerman and L. Ostrowsky and Wen, {P. Y.}",

note = "Funding Information: Supported by the Amos Wasgatt, Will Kraft, and Samuel Longo Brain Tumor Research Funds. ",

year = "2006",

month = jul,

doi = "10.1212/01.wnl.0000223844.77636.29",

language = "English (US)",

volume = "67",

pages = "156--158",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

AU - Doherty, L.

AU - Gigas, D. C.

AU - Kesari, S.

AU - Drappatz, J.

AU - Kim, R.

AU - Zimmerman, J.

AU - Ostrowsky, L.

AU - Wen, P. Y.

N1 - Funding Information: Supported by the Amos Wasgatt, Will Kraft, and Samuel Longo Brain Tumor Research Funds.

PY - 2006/7

Y1 - 2006/7

N2 - Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.

AB - Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.

UR - http://www.scopus.com/inward/record.url?scp=33746807790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746807790&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000223844.77636.29

DO - 10.1212/01.wnl.0000223844.77636.29

M3 - Article

C2 - 16832099

AN - SCOPUS:33746807790

SN - 0028-3878

VL - 67

SP - 156

EP - 158

JO - Neurology

JF - Neurology

IS - 1

ER -

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this